| 1 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 9,284 |
| 2 | Towards a unified paradigm for sequence‐based identification of fungi | Molecular Ecology | 2013 | 3,472 |
| 3 | Improved software detection and extraction of ITS1 and ITS2 from ribosomal ITS sequences of fungi and other eukaryotes for analysis of environmental sequencing data | Methods in Ecology and Evolution | 2013 | 1,318 |
| 4 | Neurofilament light chain as a biomarker in neurological disorders | Journal of Neurology, Neurosurgery and Psychiatry | 2019 | 1,063 |
| 5 | Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis | Annals of Neurology | 2017 | 1,021 |
| 6 | Biomarkers for Alzheimer's disease: current status and prospects for the future | Journal of Internal Medicine | 2018 | 815 |
| 7 | CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts | Alzheimer's and Dementia | 2018 | 696 |
| 8 | Vascular dysfunction—The disregarded partner of Alzheimer's disease | Alzheimer's and Dementia | 2019 | 601 |
| 9 | The consequences of fetal growth restriction on brain structure and neurodevelopmental outcome | Journal of Physiology | 2016 | 517 |
| 10 | sTREM
2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers | EMBO Molecular Medicine | 2016 | 487 |
| 11 | Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia | Nature Neuroscience | 2016 | 475 |
| 12 | Core candidate neurochemical and imaging biomarkers of Alzheimer's disease | Alzheimer's and Dementia | 2008 | 473 |
| 13 | Protective Role of Reactive Astrocytes in Brain Ischemia | Journal of Cerebral Blood Flow and Metabolism | 2008 | 470 |
| 14 | Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype | Alzheimer's and Dementia | 2019 | 469 |
| 15 | International criteria for electrocardiographic interpretation in athletes: Consensus statement | British Journal of Sports Medicine | 2017 | 421 |
| 16 | CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease | Annals of Clinical and Translational Neurology | 2016 | 407 |
| 17 | Salivary secretion in health and disease | Journal of Oral Rehabilitation | 2018 | 406 |
| 18 | Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study | Lancet Neurology, The | 2020 | 373 |
| 19 | CSF biomarker variability in the Alzheimer's Association quality control program | Alzheimer's and Dementia | 2013 | 365 |
| 20 | Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study | Alzheimer's and Dementia | 2018 | 353 |
| 21 | Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s
continuum
when only subtle changes in Aβ pathology are detected | EMBO Molecular Medicine | 2020 | 344 |
| 22 | Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid | Alzheimer's and Dementia | 2016 | 329 |
| 23 | The “Saltin–Grimby Physical Activity Level Scale” and its application to health research | Scandinavian Journal of Medicine and Science in Sports | 2015 | 314 |
| 24 | Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease | Alzheimer's and Dementia | 2015 | 302 |
| 25 | The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? | Alzheimer's and Dementia | 2014 | 274 |
| 26 | Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects | Alzheimer's and Dementia | 2010 | 266 |
| 27 | Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic | Alzheimer's and Dementia | 2017 | 263 |
| 28 | Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease | EMBO Molecular Medicine | 2016 | 259 |
| 29 | Consensus guidelines for lumbar puncture in patients with neurological diseases | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring | 2017 | 252 |
| 30 | Lipopolysaccharide‐induced alteration of mitochondrial morphology induces a metabolic shift in microglia modulating the inflammatory response in vitro and in vivo | Glia | 2019 | 238 |
| 31 | Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study | Alzheimer's and Dementia | 2016 | 226 |
| 32 | One-year outcome in the European multicentre study on iNPH | Acta Neurologica Scandinavica | 2012 | 206 |
| 33 | Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum | Alzheimer's and Dementia | 2020 | 204 |
| 34 | The European iNPH Multicentre Study on the predictive values of resistance to CSF outflow and the CSF Tap Test in patients with idiopathic normal pressure hydrocephalus | Journal of Neurology, Neurosurgery and Psychiatry | 2013 | 201 |
| 35 | The Vascular Impairment of Cognition Classification Consensus Study | Alzheimer's and Dementia | 2017 | 201 |
| 36 | Plasma neurofilament light chain predicts progression in progressive supranuclear palsy | Annals of Clinical and Translational Neurology | 2016 | 198 |
| 37 | Alcohol withdrawal syndrome: mechanisms, manifestations, and management | Acta Neurologica Scandinavica | 2017 | 195 |
| 38 | Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group | Alzheimer's and Dementia | 2022 | 191 |
| 39 | Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays | Alzheimer's and Dementia | 2023 | 187 |
| 40 | Inflammatory biomarkers in Alzheimer's disease plasma | Alzheimer's and Dementia | 2019 | 178 |
| 41 | Pathways to Alzheimer's disease | Journal of Internal Medicine | 2014 | 176 |
| 42 | Insulin‐like growth factor 1 has multisystem effects on foetal and preterm infant development | Acta Paediatrica, International Journal of Paediatrics | 2016 | 167 |
| 43 | Cerebrospinal fluid neurogranin and
YKL
‐40 as biomarkers of Alzheimer's disease | Annals of Clinical and Translational Neurology | 2016 | 166 |
| 44 | Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau | Alzheimer's and Dementia | 2022 | 165 |
| 45 | 18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease | EMBO Molecular Medicine | 2017 | 164 |
| 46 | The effect of neurodegenerative diseases on the subventricular zone | Nature Reviews Neuroscience | 2007 | 163 |
| 47 | Alcohol consumption and alcohol problems after bariatric surgery in the swedish obese subjects study | Obesity | 2013 | 163 |
| 48 | Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease | Alzheimer's and Dementia | 2019 | 159 |
| 49 | Elevated CSF GAP‐43 is Alzheimer's disease specific and associated with tau and amyloid pathology | Alzheimer's and Dementia | 2019 | 156 |
| 50 | Bipolar disorder and its relation to major psychiatric disorders: a family‐based study in the Swedish population | Bipolar Disorders | 2015 | 155 |